February 27, 2025 How the House’s Budget Plan Sets the Stage for a Fiscal Showdown
Tesla: Capturing Opportunity in a Contrarian Market
Microsoft: Resilient Amid Sell-Off, 'Buy' Stance Reaffirmed
3M: Valuation Challenges Amidst Limited Growth Prospects
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
January 21, 2025 Bitcoin Is Great, but Here Are 3 Altcoins Worth Considering in 2025
Teva (TEVA) stock forecast for 2026
Updated: March 2, 2025 (18:56)
Sector: HealthcareThe share price of Teva Pharmaceutical Industries Lim. (TEVA) (TEVA) now
50/200 Day Moving Average: $19.49 / $17.88
This figure corresponds to the Average Price over the previous 50/200 days. For Teva stocks, the 50-day moving average is the resistance level today.
For Teva stocks, the 200-day moving average is the resistance level today.
Are you interested in Teva Pharmaceutical Industries Lim. (TEVA) stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Teva stock price in 2026. How much will one Teva share be worth in 2026? Is it worth taking profit / loss on TEVA stock now or waiting? What are analysts' forecasts for Teva stock?
We forecast Teva stock performance using neural networks based on historical data on TEVA stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account. This corporation stock prediction results are shown below and presented as a graph, table and text information.
Teva Pharmaceutical Industries Lim. (TEVA) stock forecasts are adjusted once a day based on the closing price of the previous trading day.
The minimum target price for Teva analysts is $23.9. Today 200 Day Moving Average is the resistance level (17.88 $). 50 Day Moving Average is the resistance level (19.49 $).
Historical and forecast chart of Teva Pharmaceutical Industries Lim. (TEVA) stock
The chart below shows the historical price of Teva stock and a prediction chart for the next year. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the TEVA stock price can be found in the table below.
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generics, specialty drugs and biopharmaceutical products in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic agents in a variety of dosage forms, including tablets, capsules, injections, inhalers, liquids, ointments and creams. It also develops, manufactures and markets active pharmaceutical ingredients. In addition, the company provides specialized medicines for use in the central nervous system and respiratory indications. In addition, its products in the central nervous system and pain areas include Copaxone for the treatment of relapsing forms of MS; ADZHOVIY for the prophylactic treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease. In addition, the company’s products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair / Cinqaero and AirDuo RespiClick / ArmonAir RespiClick / AirDuo Digihaler for asthma and chronic obstructive pulmonary disease, as well as Bendeka products , Trisenox, Lonquex and Tevagrastim / Ratiograstim in the cancer market. She has cooperation agreements with Otsuka Pharmaceutical Co. LTD. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petah Tikva, Israel.
Teva (TEVA) Forecast for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 20.57 | 18.73 | 21.86 | 14.31 % |
| Feb | 20.31 | 19.04 | 22.26 | 14.45 % |
| Mar | 18.68 | 17.88 | 19.85 | 9.94 % |
| Apr | 19.76 | 17.90 | 20.52 | 12.79 % |
| May | 19.86 | 19.03 | 21.60 | 11.91 % |
| Jun | 19.03 | 16.69 | 20.46 | 18.45 % |
| Jul | 22.04 | 20.10 | 23.60 | 14.80 % |
| Aug | 23.21 | 20.68 | 25.62 | 19.28 % |
| Sep | 23.84 | 21.28 | 25.21 | 15.58 % |
| Oct | 22.54 | 20.16 | 25.21 | 20.03 % |
| Nov | 19.62 | 18.24 | 20.75 | 12.10 % |
| Dec | 18.65 | 16.59 | 20.80 | 20.23 % |
Teva information and performance
5 BAZEL ST, P O B 3190, PETACH TIKVA, IL
Market capitalization of the Teva Pharmaceutical Industries Lim. (TEVA) is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of TEVA shares in the company outstanding by the market price of one share.
EBITDA of Teva is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Teva price target for 2026 by month
Target values for the price of one Teva share for Jan 2026.
In Jan, the Positive dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 14.307% volatility is expected.
Pessimistic target level: 18.73
Optimistic target level: 21.86
Target values for the price of one Teva share for Feb 2026.
In Feb, the Negative dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 14.453% volatility is expected.
Pessimistic target level: 19.04
Optimistic target level: 22.26
Target values for the price of one Teva share for Mar 2026.
In Mar, the Negative dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 9.940% volatility is expected.
Pessimistic target level: 17.88
Optimistic target level: 19.85
Target values for the price of one Teva share for Apr 2026.
In Apr, the Positive dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 12.789% volatility is expected.
Pessimistic target level: 17.90
Optimistic target level: 20.52
Target values for the price of one Teva share for May 2026.
In May, the Positive dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 11.912% volatility is expected.
Pessimistic target level: 19.03
Optimistic target level: 21.60
Target values for the price of one Teva share for Jun 2026.
In Jun, the Negative dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 18.452% volatility is expected.
Pessimistic target level: 16.69
Optimistic target level: 20.46
Target values for the price of one Teva share for Jul 2026.
In Jul, the Positive dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 14.798% volatility is expected.
Pessimistic target level: 20.10
Optimistic target level: 23.60
Target values for the price of one Teva share for Aug 2026.
In Aug, the Positive dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 19.275% volatility is expected.
Pessimistic target level: 20.68
Optimistic target level: 25.62
Target values for the price of one Teva share for Sep 2026.
In Sep, the Positive dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 15.582% volatility is expected.
Pessimistic target level: 21.28
Optimistic target level: 25.21
Target values for the price of one Teva share for Oct 2026.
In Oct, the Negative dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 20.029% volatility is expected.
Pessimistic target level: 20.16
Optimistic target level: 25.21
Target values for the price of one Teva share for Nov 2026.
In Nov, the Negative dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 12.103% volatility is expected.
Pessimistic target level: 18.24
Optimistic target level: 20.75
Target values for the price of one Teva share for Dec 2026.
In Dec, the Negative dynamics for Teva Pharmaceutical Industries Lim. (TEVA) shares will prevail with possible monthly volatility of 20.229% volatility is expected.
Pessimistic target level: 16.59
Optimistic target level: 20.80
Teva (TEVA) stock dividend
Teva last paid dividends on 11/27/2017. The next scheduled payment will be on 12/12/2017. The amount of dividends is $None per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
